KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Capital BDC (CCAP) Cash & Equivalents (2021 - 2026)

Crescent Capital BDC filings provide 5 years of Cash & Equivalents readings, the most recent being $5.0 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 50.22% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 million, a 50.22% decrease, with the full-year FY2025 number at $5.0 million, down 50.22% from a year prior.
  • Cash & Equivalents hit $5.0 million in Q4 2025 for Crescent Capital BDC, up from $2.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $17.1 million in Q3 2024 to a low of $2.1 million in Q3 2025.
  • Median Cash & Equivalents over the past 5 years was $6.4 million (2021), compared with a mean of $7.0 million.
  • The widest YoY moves for Cash & Equivalents: up 252.22% in 2025, down 87.81% in 2025.
  • Crescent Capital BDC's Cash & Equivalents stood at $2.1 million in 2021, then surged by 202.46% to $6.4 million in 2022, then dropped by 19.84% to $5.1 million in 2023, then surged by 97.54% to $10.1 million in 2024, then crashed by 50.22% to $5.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $5.0 million (Q4 2025), $2.1 million (Q3 2025), and $9.7 million (Q2 2025) per Business Quant data.